## **AMENDMENTS TO THE CLAIMS**

Claim 1 (Previously amended): A method to enhance bone formation in a vertebrate animal which method comprises administering to a vertebrate animal in need of such treatment an effective amount of a compound that inhibits proteasomal activity and said compound being selected from the group consisting of a peptidyl aldehyde, pentoxyfilline (PTX) and epoxomicin, whereby bone formation is enhanced in said vertebrate animal.

Claim 2-4 (Cancelled)

Claim 5 (Previously amended): The method of claim 1 wherein said vertebrate animal is characterized by a condition selected from the group consisting of osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, metastatic bone disease, osteolytic bone disease, and post-plastic surgery.

Claim 6 (Original): The method of claim 1 which further comprises administering to said subject one or more agents that promote bone growth or that inhibit bone resorption.

Claim 7 (Original): The method of claim 6 wherein said agents are selected from the group consisting of bone morphogenetic factors, anti-resorptive agents, osteogenic factors, cartilage-derived morphogenetic proteins, growth hormones, estrogens, bisphosphonates, statins and differentiating factors.

Claims 8-18 (Cancelled)

Claim 19 (Original): The method of claim 1, wherein the compound is a peptidyl aldehyde.

Claim 20 (Original): The method of claim 1, wherein the compound is pentoxyfilline (PTX).

Claim 21 (Original): The method of claim 1, wherein the compound is epoxomicin.

Claim 22 (Original): The method of claim 1, wherein the vertebrate animal is a human.

Claim 23 (Original): The method of claim 1, wherein the vertebrate animal is a non-human mammal.